Accessibility Menu
Xenous logo

Xenous(OTC) XITO

Market Cap$4.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-94%
5 Year-85%
1 Year-28%
1 Month-56%
$0.01
+0.00%
+0.00Today
Xenous last closing stock price
MetricPriceDate
Last closeUSD 0.012026-08-28
Xenous stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-56.43%USD 0.012026-07-15
1 month-56.43%USD 0.012026-07-15
3 month-12.86%USD 0.012026-05-14
Year to date+7.02%USD 0.012025-11-05
1 year-28.24%USD 0.012025-07-02
3 year-84.75%USD 0.042023-06-26
5 year-84.75%USD 0.042021-08-19
Since inception-93.52%USD 0.092017-11-09

Xenous Financials at a Glance

Market Cap

$4.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$64.91K

EPS (TTM)

-$0.00

P/E Ratio

-61.00

Dividend

$0.00

Beta (Volatility)

-0.22 (Low)

Price

$0.01

Volume

25

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.04

Estimated Earnings Date

Feb 12, 2026

XITO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xenous

Xenous does not offer products or services to the public. The company seeks businesses or assets to acquire. It currently has no operations or employees.

What’s (Not) on the Shelf: Products and Services

  • Business Acquisition: Focuses on identifying and acquiring operating businesses or assets (0% of revenue).
  • Due Diligence: Conducts research on potential acquisition targets, such as agricultural companies (0% of revenue).
  • Shell Company Activities: Maintains legal and reporting status while seeking new business opportunities (0% of revenue).

Growth and Expansion: The Waiting Game

  • Changed name from M101 Corp. to Xenous in November 2019.
  • Currently conducting due diligence on a Malaysia-based Aquilaria tree products company (2025).
  • No completed acquisitions or partnerships as of June 2025.
  • Operates as a shell company since at least 2017 IPO.

What Makes Xenous Stand Out (or Not)

Xenous is a shell company, meaning it has no active business operations. Its main activity is searching for businesses to acquire. The company relies on its majority shareholder for funding and has no global operations or distribution.

Five Things You Need to Know

  • No revenue reported for any period through June 2025.
  • Net loss was $15,311 in Q1 2025, a 4.1% improvement from Q1 2024 (net loss of $15,971).
  • Most funding comes from advances and loans by majority shareholder Smartex Investment Ltd.
  • Total liabilities were $918,933 as of June 30, 2025, with no assets.
  • Ongoing due diligence on a potential acquisition in Malaysia, focused on Aquilaria tree products.

Bottom Line

Xenous is a shell company with no operations, revenue, or products. Its future depends on acquiring a business and continued support from its main shareholder.

AI Generated • Apr 16, 2026

Industry

Capital Markets

Sector

Financials

CEO

Ye Earn Chan

Website

www.xenous.co

Headquarters

Hong Kong, HK

XITO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

7.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

-1.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

760.25M

Volume

25

Avg. Volume

2.93K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$15.64K

EBITDA

$15.51K

Operating Cash Flow

-$54.63M

Capital Expenditure

$0.00

Free Cash Flow

-$54.63M

Cash & ST Invst.

$0.00

Total Debt

$926.28K

Xenous Performance Analysis

Xenous annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 0N/A
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
Xenous sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31N/A
Q12025-06-30N/A
Q22025-09-30N/A
Q32025-12-31N/A
Xenous annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -0.00N/A
20232023-03-31USD -0.000.0%
20242024-03-31USD -0.000.0%
20252025-03-31USD -0.000.0%
Xenous sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31N/A
Q12025-06-30100.0%
Q22025-09-30N/A
Q32025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$15.52K

-4.2%

EBITDA

-$15.52K

-4.2%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$0.00

N/A

Total Debt

$926.28K

+7.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$926.28K

+7.1%

Return on Assets

0.00%

N/A

Return on Invested Capital

1.65%

N/A

Free Cash Flow

-$15.33K

+6.2%

Operating Cash Flow

-$15.33K

+6.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMAQInternational Media Acquisition Corp.
$10.20+0.00%
CNGLCanna-Global Acquisition Corp
$9.05+0.00%
CMCAFPiermont Valley Acquisition Corp. Class A
$13.00+0.00%
WAYSWave Sync Corp.
$4.48+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About XITO

What is the current price of Xenous?

Xenous is trading at $0.01 per share.

What is the 52-week range for Xenous?

Over the past 52 weeks, Xenous has traded between $0.00 and $0.04.

How much debt does Xenous have?

As of the most recent reporting period, Xenous reported total debt of $926.28K.

How much cash does Xenous have on hand?

Xenous reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Xenous’s dividend yield?

Xenous does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services